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Abstract
The genetic study of disease-associated phenotypes has become common because such phenotypes
are often easier to measure and in many cases are under greater genetic control than the complex
disease itself. Some disease-associated phenotypes are rare, however, making it difficult to evaluate
their effects due to small informative sample sizes. In addition, analyzing numerous phenotypes
introduces the issue of multiple comparisons. To address these issues, we have developed a
hierarchical model (HM) for multiple phenotypes that provides more accurate effect estimates with
a lower false-positive rate. We evaluated the validity and power of HM in association studies of
multiple phenotypes using randomly selected cases and controls from the simulated data set in the
Genetic Analysis Workshop 14. In particular, we first analyzed the association between each of the
12 subclinical phenotypes and single-nucleotide polymorphisms within the known causal loci using
a conventional logistic regression model (LRM). Then we added a second-stage model by regressing
all of the logistic coefficients of the phenotypes obtained from LRM on a Z matrix that incorporates
the clinical correlation of the phenotypes. Specially, the 12 phenotypes were grouped into 3
clusters: 1) communally shared emotions; 2) behavioral related; and 3) anxiety related. A semi-
Bayes HM effect estimate for each phenotype was calculated and compared with those from LRM.
We observed that using HM to evaluate the association between SNPs and multiple related
phenotypes slightly increased power for detecting the true associations and also led to fewer false-
positive results.
Background
Complex diseases are most commonly evaluated in asso-
ciation studies as a single phenotype. However, they often
comprise numerous phenotypes with varying degrees of
interrelatedness. For example, in the study of alcoholism,
brain electrophysiological measures (e.g., electroencepha-
lograms and event-related potenials) can be evaluated as
biological markers for developing alcoholism. Focusing
on such disease-associated phenotypes can help improve
a study if they are under greater genetic control or easier to
measure than the ultimate disease endpoint (e.g., alcohol-
ism). Nevertheless, analyzing the effect of genes on
numerous phenotypes introduces issues of multiple com-
parisons, and can lead to imprecise estimates of associa-
tion if the number of individuals exhibiting a disease-
associated phenotype is limited.
These issues can be addressed by using a hierarchical
model (HM) that compromises between analyses of a sin-
gle phenotype and numerous disease-associated pheno-
types. Specifically, this approach shrinks conventional
estimates for phenotypes toward a prior mean distin-
guished by their biologically interrelated nature. Previous
work has shown that HM can improve conventional esti-
mation of the association between disease(s) and expo-
sures [1-4], fine-mapping by linkage disequilibrium
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modeling [5], and gene × environment interaction [6-8].
Here, we show how HM can be used to evaluate the asso-
ciation between genetic factors and multiple disease-asso-
ciated phenotypes, and evaluate the performance of HM
by comparing power and false-positive rates (FPR) with a
conventional logistic regression model (LRM).
Comparison of power when evaluating multiple phenotypes: HM (solid lines) versus LRM (dotted lines) Figure 1
Comparison of power when evaluating multiple phenotypes: HM (solid lines) versus LRM (dotted lines).
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Methods
We used the simulated dataset from the Genetic Analysis
Workshop 14 (GAW14) to sample cases and controls for
association analyses. Specially, we randomly selected 1
case per family across 4 populations (Aipotu, Karangar,
Danacaa, New York City), which gives a total of 350 cases
per replicate. Then 50 controls per replicate were pooled
together and used as a "population" (n = 5,000) for con-
trol selection. In light of the limited number of cases, we
selected two controls per case, leading to a total of 1,050
subjects per replicate (350 cases, 700 controls).
For the 12 phenotypes, we first analyzed each using a con-
ventional logistic regression model:
logit (Pr (Ym = 1) | gT) = µm + gTβm + sex βsex,   (1)
where binary traits Y1... Ym (m = 12) refer to the pheno-
types a - l in the simulated data, and g is the single-nucle-
otide polymorphism (SNP)-specific coding for each
individual. For simplicity's sake, we assumed a dominant
model for the minor allele, but not for D6, because its
common allele is truly functional. Sex was included in
Equation 1 because of its potential role in psychiatric dis-
orders. Our HM attempted to improve the first-stage esti-
mates of the SNP-effects on the phenotypes (βm) by
adding the following second-stage linear regression
model:
β = Zπ + U   (2)
where U ~ Nm (0m, τ 2). Here, Z is a 12 × 3 matrix contain-
ing second-stage covariates defining 3 clusters of the 12
phenotypes: 1) communally shared emotions; 2) behav-
ioral related; and 3) anxiety related. In particular, for each
phenotype, the corresponding elements in Z are set equal
to 1 if they have been defined as being within one of the
clusters, and 0 otherwise. π is a column vector of coeffi-
cients corresponding to the effects of the second-stage cov-
ariates on the SNP (i.e., cluster-level effects). In this way,
Z incorporates into a second stage the clinical correlation
of the phenotypes, whereby the estimate of each βm "bor-
rows" information from the other estimates. We fixed τ as
0.354, using a semi-Bayes HM (in empirical-Bayes one
would estimate the τ). This value implies a four-fold range
of residual odds ratios for the SNP on phenotypes (exp(±
3.92*0.354)) after accounting for the relations defined in
Z [5]. Finally, we compared the estimates of phenotype
effects obtained from the conventional LRM approach
(Equation 1) to those obtained from HM (Equations 1
and 2 combined).
To compare the models, we bought 10 packets of markers,
which contained 4 disease loci and 2 modifier genes. Four
markers were chosen as the causal surrogates because they
either provided the highest power compared with other
SNPs in the same region (D1, D3, and D4) or had higher
power while also being informative for the power com-
parison (i.e., with less than 100% power for both the HM
and LRM (D2)). Together with two modifier genes, which
were defined as D5 and D6, a total of 6 SNPs were used
for the power comparison. We calculated power as the
proportion of replicates in which the tested SNP was sta-
tistically significantly associated with a phenotype at an
alpha level = 0.05.
A total of 190 SNPs were used for the type I error compar-
isons (excluding 10 microsatellite markers). Phenotype i
Comparison of FPR when evaluating multiple phenotypes: HM (solid lines) versus LRM (dotted lines) Figure 2
Comparison of FPR when evaluating multiple phenotypes: HM (solid lines) versus LRM (dotted lines).
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and j were simulated randomly, so any statistically signif-
icant association with these phenotypes is considered a
false positive. For each SNP, the FPR was defined as the
proportion of replicates showing association at a signifi-
cance level of 0.05. We analyzed 190 SNPs and compared
the validity of HM and LRM by estimating the proportion
of SNPs with FPR of greater than 5%.
In order to maintain the validity of maximum likelihood
estimates (MLE) from LRM when there were no observa-
tions for a given phenotype and genotype combination,
four "pseudo" subjects were added in the replicates for the
type I error comparisons (190 SNPs) and power compari-
son only in D6. Specificially, each of these additional sub-
jects represents 1 of the 4 possible combinations of
phenotype and genotype. Both conventional LRM and
HM analyses were undertaken with SAS software (version
8.2, SAS Institute, Cary, NC), and the codes for HM are
available at http://www.epibiostat.ucsf.edu/witte_lab/.
Results
We found that HM has slightly higher power than LRM
with mean of 58.8% vs. 56.5% (Figure 1). The largest
improvement was 19% for the association between phe-
notype a  and D3. But the conventional LRM provided
slightly higher power for some of the associations too, for
example: phenotype a and D1. No power is shown for the
random phenotypes i and j.
More striking was the decrease in FPR provided by the HM
in comparison with the LRM (to the right of the vertical
line in Figure 2). With HM, 27 (14%) and 37 (19%) out
of 190 SNPs total showed FPR greater than 5% for pheno-
types i and j, respectively. In contrast, 61 (32%) and 70
(37%) of the tested SNPs showed FPR greater than 5%
when using LRM. Testing the difference in FPR between
the HM and LRM approaches for phenotypes i and j gave
p-values < 0.001.
Discussion
We observed that using HM to evaluate the association
between SNPs and multiple disease-associated pheno-
types led to substantially fewer false positives, while
slightly increasing power for detecting the true associa-
tions. HM can decrease the false-positive rates because the
estimate for each phenotype borrows information from
other biologically similar traits, through a second-stage Z
matrix. In the present study, we grouped phenotypes into
three clusters according to the similarity of their clinical
characteristics.
Note that we based our power calculations on the surro-
gate markers; nevertheless, the results (Figure 1) ulti-
mately reflect the corresponding causal effect. Specifically,
phenotypes b - h were controlled by D2, D3, and D4, and
the markers in those regions provided power of 40–100%.
In addition, only the SNP in the D4 region showed an
association with the single-gene phenotype l, not the oth-
ers. Two exceptions here are the association between phe-
notype a and the SNP in the D2 region, and an association
between phenotype k  and the SNP in the D3 region,
which are not the true causal loci. This may be explained
by the allelic association among these genes. For example,
D1 and D3 are causally associated with phenotype a, and
also associated with D2; therefore any association
between D2 and phenotype a  may simply reflect the
effects of D1 and D3. Regardless, these relations should
not affect our comparison of HM and LRM.
We did not use the "truth" for the simulations, since in
practice this knowledge is not available. However, previ-
ous simulation studies based on the true underlying
model between disease and exposures [4] or known LD
pattern [5] indicate that hierarchical modeling offers
worthwhile improvement over ordinary maximum-likeli-
hood. Future work might also look at hierarchical mode-
ling when the interrelated network of phenotypes and
trait loci is known with certainty.
Conclusion
Genetic association studies may attempt to reduce pheno-
type heterogeneity by evaluating subclinical and measur-
able traits instead of the primary disease of interest. Such
disease-associated phenotypes may be under similar
genetic control, although other genes and/or environmen-
tal factors contribute to the difference among them. By
incorporating this information into a higher-level model,
HM helps address problems of multiple comparisons
while providing more precise estimates than conventional
analyses.
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